Calls for Senate to Also Pass Legislation Before Deadline Expires WASHINGTON, D.C. (September 19, 2007) -- Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood released the following statement following passage by the House of Representatives of the reauthorization of the Prescription Drug User Fee Act (PDUFA) today: “We are the pleased the House has voted to reauthorize PDUFA. The final package will help enhance and improve drug safety while providing the resources necessary for the Food and Drug Administration (FDA) to continue the efficient and comprehensive review of new drugs and biologics. “We encourage the Senate to pass this legislation before the current PDUFA agreement expires at the end of the month. The FDA will be forced to notify staff of the possibility of a reduction in force if this legislation is not signed into law in the next few days, and the loss of experienced reviewers would be detrimental to the biotech industry and the patients we serve.” Since its inception in 1992, PDUFA has provided FDA with the resources necessary to review more than 1,100 new medicines, and to reduce review times for innovative drugs and biologics, providing patients and doctors with earlier access to breakthrough treatments. About BIO BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and 31 other nations. BIO members are involved in the research and development of healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the annual BIO International Convention, the global event for biotechnology. www.bio.org Upcoming BIO Events
· BIO Mid-America VentureForum 2007 Sep. 24–26, 2007 Milwaukee, WI · BIO InvestorForum 2007 October 9-11, 2007 San Francisco, CA · Pacific Rim Summit on Industrial Biotechnology and Bioenergy
November 14-16 Honolulu, Hawaii · BIO International Convention
June 17–20, 2008 San Diego, CA ### | 
Printer Friendly